All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
This article was written by Dr Mary Gleeson from the Royal Marsden Hospital in London and Surrey and her co-authors from various centers around the UK, and was published in the British Journal of Haematology on 1st of August 2016. The article describes the data from a subgroup analysis that evaluated the outcomes of patients (n=50) with primary mediastinal B-cell lymphoma (PMBL), which is a distinct type of diffuse large B-cell lymphoma (DLBCL); treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) with or without radiotherapy (RT) within the randomized phase III UK NCRI R-CHOP-14 trial (six cycles of R-CHOP every 14 days plus 2 cycles of rituximab) versus the R-CHOP-21 trial (8 cycles of R-CHOP every 21 days). The primary endpoint of the study was to determine overall survival (OS) and the secondary endpoints were to evaluate progression free survival (PFS) and response rate. Response following chemotherapy with R-CHOP was evaluated by computer tomography (CT) scans of the thorax, abdomen and pelvis with or without neck.
Although it was the largest PMBL cohort treated by R-CHOP, the number of patients was small and therefore more robust studies need to be established that would have more significant multivariate analysis; however, the data demonstrated in this study does provide evidence of R-CHOP efficacy in the management of PMBL and provides the ground work for other clinical trials. Dose-intensity should also be considered in future trials for this specific subtype of DLBCL.
We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median followup of 7.2 years the 5-year progression-free survival and overall survival was 79.8% and 83.8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox